摘要
目的探讨经导管肝动脉化疗栓塞(TACE)联合经皮微波消融(PMCT)治疗肝细胞癌的临床疗效和安全性。方法将82例肝癌患者分为联合组(TACE+PMCT)45例,对照组(单纯TACE)37例,随访1～2年,对比两组治疗效果和不良反应。结果联合组肿瘤完全坏死和AFP水平下降>50%的患者均高于对照组,差异有统计学意义(P<0.05);联合组的1年、2年生存率均比对照组高,1年、2年复发率比对照组低,两组均未发生严重不良反应。结论 TACE+PMCT治疗直径>3cm的肝细胞癌疗效确切,安全可行。
Objective To investigate the efficacy and safety of combination of transcatheter arterial chemo-embolization （TACE） and percutaneous microwave coagulation therapy （PMCT） in treatment of hepatocellular carcinoma （PHC）.Methods 82 cases of PHC were divided into combined group （TACE＋PMCT,n=45） and control group （only TACE,n=37）.Patients were followed up for 1 to 2 years,and the therapeutic effects and side effects were compared between the two groups.Results The patients with tumor completely necrosis and AFP level lower than 50% in combined group were significantly more than those in control group （P0.05）;the one year and two years survival rate in combined group were greatly higher than those of control group,and the recurrence rate was lower than control group;no severe side effect was observed in two groups.Conclusion TACE＋PMCT is effective and safe in treatment of PHC of more than 3 cm in diameter.
出处
《微创医学》
2010年第4期333-335,共3页
Journal of Minimally Invasive Medicine
关键词
肝细胞癌
经导管肝动脉化疗栓塞
经皮微波消融治疗
联合
Hepatocellular Carcinoma
Transcatheter arterial chemo-embolization
Percutaneous microwave coagulation Therapy
Combination
